Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Takahiko Saida
Qi Hao
Michihiro Kanda
Yumiko Tani
机构：
[1] Irino Clinic Inc,Kansai Multiple Sclerosis Centre
[2] Biogen Japan Ltd,Kansai Multiple Sclerosis Centre
[3] Kyoto Neurology Clinic,undefined
来源：
BMC Neurology | / 23卷
关键词：
Annual Relapse Rate; Japanese; Magnetic resonance imaging; Natalizumab; Relapsing-remitting multiple sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Long-term effects of natalizumab on MRI activity and clinical outcomes in Japanese patients with relapsing-remitting multiple sclerosis
    Saida, Takahiko
    Hao, Qi
    Kanda, Michihiro
    Tani, Yumiko
    [J]. BMC NEUROLOGY, 2023, 23 (01)
  • [2] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [3] Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study
    Comi, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Adeniji, Abidemi K.
    Dangond, Fernando
    Giovannoni, Gavin
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11 : 1 - 11
  • [4] Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort
    Bigaut, K.
    Fabacher, T.
    Kremer, L.
    Ongagna, J. -C.
    Kwiat-Kowski, A.
    Sellal, F.
    Ferriby, D.
    Courtois, S.
    Vermersch, P.
    Collongues, N.
    Zephir, H.
    De Seze, J.
    Outteryck, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 536 - 536
  • [5] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [6] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    [J]. NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [7] Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis
    Traboulsee, Anthony
    Uitdehaag, Bernard M. J.
    Kappos, Ludwig
    Sandberg-Wollheim, Magnhild
    Li, David
    Jongen, Peter
    Constantinescu, Cris C.
    Verdun, Elisabetta
    Cornelisse, Peter
    [J]. NEUROLOGY, 2010, 74 (09) : A100 - A100
  • [8] Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis
    Wiendl, H.
    Butzkueven, H.
    Trojano, M.
    Goodin, D.
    Kappos, L.
    Desgrandchamps, D.
    [J]. MULTIPLE SCLEROSIS, 2009, 15 (09): : S248 - S248
  • [9] Long-term effect of natalizumab in a French cohort of patients with relapsing-remitting multiple sclerosis: TYSTEN cohort
    Bigaut, Kevin
    Fabacher, Thibaut
    Collongues, Nicolas
    Kremer, Laurent
    Fleury, Marie-Celine
    Ongagna, Jean-Claude
    De Seze, Jerome
    [J]. NEUROLOGY, 2018, 90
  • [10] Effect of natalizumab on disease activity in relapsing-remitting multiple sclerosis patients
    Agiela, Mabroka I. M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP5 - NP5
12345